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Since their early 1990s, the chemokine receptor family of G protein-coupled receptors (GPCRs) has been
the source of much pharmacological endeavour. Best known for their key roles in recruiting leukocytes to
sites of infection and inﬂammation, the receptors present themselves as plausible drug targets for
therapeutic intervention. In this article, we will focus our attention upon CC Chemokine Receptor Four
(CCR4) which has been implicated in diseases as diverse as allergic asthma and lymphoma. We will
review the discovery of the receptors and their ligands, their perceived roles in disease and the successful
targeting of CCR4 by both small molecule antagonists and monoclonal antibodies. We will also discuss
future directions and strategies for drug discovery in this ﬁeld.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
1.1. The chemokine superfamily
The chemokine superfamily of proteins serves to coordinate a
variety of immune system functions that link both innate and
adaptive immunity (Zlotnik and Yoshie, 2012) and is best known
for its key role in the recruitment and retention of leukocyte po-
pulations in both homeostasis and immune responses to patho-
gens (Viola and Luster, 2008). The superfamily consists of over
twenty GPCRs and around 40 chemokine ligands (Table 1) which
act as receiver and signal respectively, to guide leukocytes be-
tween tissue compartments (Bachelerie et al., 2013). Movement of
leukocytes is along a gradient of chemokine, a process known as
chemotaxis, which is sensed by the cell surface chemokine re-
ceptors. Binding of the chemokine ligand to the extracellular face
of the receptor activates multiple intracellular signaling pathways,
with Pertussis toxin-sensitive G proteins of the Gαi subset and
Phosphatidylinositol-3 kinases (PI3K) playing key roles.
1.2. Aspects of signaling
Activation of chemokine receptors leads to the recruitment of
PI3K to the plasma membrane and the localized production ofr B.V. This is an open access article
.Phosphatidylinositol (3,4,5)-trisphosphate (PI (3,4,5) P3) from
Phosphatidylinositol (4,5)-bisphosphate (PI (4,5) P2). The redis-
tribution of the PI (3,4,5) P3 –speciﬁc phosphatase PTEN to the rear
of the cell results in the generation of an intracellular gradient of PI
(3,4,5) P3, which is highly enriched at the leading edge of the cell.
This results in the localization of cytosolic proteins with pleckstrin
homology (PH) domains which readily bind PI (3,4,5) P3 (Lemmon,
2007). Such proteins include Akt, GTPase activating proteins
(GAPs) and guanine-nucleotide-exchange factors (GEFs). GEFs
serve to activate small GTPases belonging to the Rho family by
stimulating the exchange of GDP for GTP, thereby activating the
protein. Activated Rho GTPases such as Cdc42 and Rac are well
known for their contribution to membrane protrusion at the
leading edge of the cell and the maintenance of cell polarity
(Weiner et al., 2002) in conjunction with members of the Wiskott-
Aldrich Syndrome Protein family, such as WASP (Symons et al.,
1996). In contrast, GAPs enhance the intrinsic GTPase activity of
the Rho family members, hydrolyzing GTP to GDP and turning off
the protein function. Accordingly, actin polymerization at the
leading edge of the cell, coupled with contraction at the rear, re-
sults in movement of the leukocyte in the direction of the sti-
mulus, i.e. along the concentration gradient (Fig. 1).
Migration proceeds as long as the chemokine receptor main-
tains intracellular signaling and actin remodeling at the leading
edge. The process is terminated by G protein receptor kinases
(GRKs) which induce C-terminal phosphorylation of the chemo-
kine receptor (Penela et al., 2014). This increases the afﬁnity forunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Human chemokine receptors and their cellular expression. Table showing the accepted cellular/tissue distribution of chemokine receptors and their ligands. Ab-
breviations: B, B-lymphocyte; Bro, Bronchial epithelial cells; Bs, basophil; DC, dendritic cell; Eo, eosinophil; Ker, keratinocytes; Mc, mast cell; Mo, monocyte; MSC, Me-
senchymal Stem cell, NK, natural killer cell; No, neutrophil; NT, neuronal tissue; LEC, lymphatic endothelial cell; P, platelets; RBC, red blood cell; SLO, secondary lymphoid
organ; Syn, Syncytiotrophoblast; T, T-lymphocytes; VEC, vascular endothelial cell (adapted from Pease, 2011).
Chemokine receptor Chemokine ligands Cellular expression Chemokine
receptor
Chemokine ligands Cellular expression
CCR1 CCL3, CCL4, CCL5, CCL7, CCL8, CCL13,
CCL14, CCL15, CCL16, CCL23
Mo, DC, Eo, Bs, T,
PMN, NK
CXCR1 CXCL5, CXCL6, CXCL8 No, Mo
CCR2 CCL2, CCL5, CCL7, CCL8, CCL13, CCL16 Mo, DC, T, Bs CXCR2 CXCL1, CXCL2, CXCL3, CXCL5,
CXCL6, CXCL7, CXCL8
No, Mo
CCR3 CCL4, CCL5, CCL7, CCL11, CCL13, CCL15,
CCL24, CCL26, CCL28
Eo, T, Bs, Mc CXCR3 CXCL4, CXCL4L1, CXCL9, CXCL10,
CXCL11,
T, B
CCR4 CCL17, CCL22 T, MC, Bro, NK, P CXCR4 CXCL12 T, B, DC, Mo
CCR5 CCL3, CCL4, CCL5, CCL7, CCL14, CCL15 Mo, DC, T CXCR5 CXCL13 T, B
CCR6 CCL20 DC, T CXCR6 CXCL16 T
CCR7 CCL19, CCL21 DC, T, B, NK
CCR8 CCL1, CCL18 Mo, T, NK XCR1 XCL1, XCL2 T, NK
CCR9 CCL25 T
CCR10 CCL27, CCL28 T CX3CR1 CX3CL1 T, NK, DC, Mo
ACKR1 (DARC) CCL2, CCL5, CCL7, CCL11, CCL13, CCL14,
CCL17,CXCL5, CXCL6,CXCL11
RBC, VEC ACKR2 (D6) CCL1,CCL5, CCL7, CCL11, CCL13,
CCL14, CCL17, CCL22
LEC, Syn
ACKR3 (CXCR7) CXCL11, CXCL12 B, MSC, NT ACKR4 (CCRL1) CCL19, CCL21, CCL25 Ker, SLO
Fig. 1. Cartoon showing a leukocyte migrating along a gradient of chemokine
(gray) in the direction of the arrow. Activation of the 7TMRs at the leading edge of
the cell activated PI3K to PIP3. The location of the phosphatase PTEN at the rear of
the cell results in an internal gradient of PIP3 , which is concentrated in the vicinity
of the receptor. This facilitates localized binding of Rho GTPases such as Cdc42 and
Rac (blue, green pink ovals) which modulate the actin cytoskeleton and contribute
to membrane protrusion in the direction of the chemokine source.
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ceptor for clathrin-coated pit mediated endocytosis and degrada-
tion or recycling. Thus as the cell encounters increasingconcentrations of chemokine, fewer and fewer receptors remain at
the cell surface to drive the intracellular signals needed for che-
motaxis and migration is inhibited. This is one potential explana-
tion for the bell-shaped chemotaxis plots observed in dose–re-
sponse experiments with increasing concentrations of chemokine.
Once thought to function solely as a means of sterically hindering
GPCR signaling and promoting receptor endocytosis (Lefkowitz,
1998), arrestin binding to GPCRs is now appreciated to induce
additional signaling programs by acting as a scaffold for the re-
cruitment of further signaling molecules such as MAP kinases
(DeWire et al., 2007; Lefkowitz and Shenoy, 2005). The sig-
niﬁcance of this in terms of chemokine signaling was ably shown
when mice deﬁcient in arrestin-2 were shown to have impaired
chemotaxis to CXCL12 (Fong et al., 2002). This has been translated
in part to the human setting by studies of CXCR4 in patients suf-
fereing from WHIM (Warts, Hypogammaglobulinemia, Infections,
and Myelokathexis) syndrome where arrestin-2 dependent phos-
phorylation of ERK1/2 has been reported to account for the hy-
perresponsiveness of the receptor to its ligand CXCL12 (Lagane
et al., 2008).
1.3. Biased agonism at chemokine receptors
Chemokines are typically promiscuous, binding to several re-
ceptors, with each receptor often having multiple ligands. This
apparent redundancy was originally thought to provide a means
by which robust responses to infectious agents could be generated
in vivo (Mantovani, 1999; Zlotnik and Yoshie, 2012). In recent
years, however, as different aspects of GPCR signaling have be-
come appreciated, it is apparent that different ligands of the same
GPCR can transduce signals via distinct cellular pathways leading
to distinct signaling outputs. This is termed functional selectivity
or biased agonism (Kenakin and Miller, 2010; Kenakin, 2012). The
predominant pathway at which ligands diverge appears to be the
arrestin-mediated signaling pathway. Several GPCRs exhibit biased
agonism with respect to arrestin signaling, including the M3-
muscarinic receptor (Poulin et al., 2010), histamine H4 receptor
(Rosethorne and Charlton, 2011), vasopressin receptors (Rahmeh
et al., 2012) and angiotensin II–type 1 receptors (Saulière et al.,
2012). In the chemokine ﬁeld, the CCR7 ligands CCL19 and CCL21
although equally active in assays of chemotaxis, have been shown
to diverge at the level of receptor endocytosis (Bardi et al., 2001;
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Kohout et al., 2004) and receptor desensitization (Penela et al.,
2014; Zidar et al., 2009). We have recently uncovered aspects of
biased signaling at the chemokine receptor CCR4, in both leuko-
cytes and lung epithelial cells, which we believe to be of sig-
niﬁcance in the setting of allergic inﬂammation, more of which
later (Ajram et al., 2014; Viney et al., 2014).
1.4. Targetting chemokines and their receptors
The inadvertent or over expression of chemokines has been
implicated in just about every disease process with an in-
ﬂammatory component, from diseases as seemingly diverse as
asthma, atherosclerosis, multiple sclerosis and rheumatoid ar-
thritis (Charo and Ransohoff, 2006; Viola and Luster, 2008). This
has led to the notion that therapeutic intervention, in the form of
chemokine receptors blockade may provide a novel therapeutic
angle. The discovery that chemokine receptors are portals for the
entry of HIV-1 into leukocytes (Alkhatib et al., 1996; Feng et al.,
1996) has fueled the drug discovery process further, with in-
hibitors of the two major receptors, CCR5 (on macrophages) and
CXCR4 (on T cells) highly prized. At the time of writing, two small
molecule antagonists of CCR5 and CXCR4 have received approval
by the relevant agencies. Miraviroc/Selsentri a CCR5 inhibitor from
Pﬁzer has been licensed for the treatment of HIV-1 infection
(MacArthur and Novak, 2008). Plerixafor, a CXCR4 antagonist ori-
ginally developed for similar purposes, has been licensed for its
ability to mobilize stem cells from the bone marrow, of use fol-
lowing administration of chemotherapeutics (Brave et al., 2010)
and is also showing early promise as a treatment for patients with
the immunosuppressive WHIM syndrome, resulting from dysre-
gulation of CXCR4 function (McDermott et al., 2011).
In this article, we will focus upon the chemokine CCR4 and its
ligands CCL17 and CCL22, which are postulated to play key roles in
the pathogenesis of allergic asthma (Pease and Horuk, 2014),
atopic dermatitis (Yamanaka and Mizutani, 2011) and a variety of
cancers, including breast cancer (Li et al., 2012), gastric cancer
(Yang et al., 2011) renal cell cancer (Liu et al., 2014) and lymphoma
(Ishida and Ueda, 2011).
1.5. CCR4 – Discovery and initial characterization
The human coding sequence for CCR4 was ﬁrst identiﬁed by
the PCR ampliﬁcation of a fragment from a cDNA library made
from the basophilic cell line KU-812 and found to have around 50%
homology to two other CC chemokine receptors identiﬁed at that
time, CCR1 and CCR2 (Power et al., 1995). The original report as-
signed CCL3 as a functional ligand for CCR4, inducing Ca2þ inﬂux
in Xenopus oocytes although this may be an artifact of the system
employed, since the authors subsequently showed that HEK-293
transfectants were unresponsive to CCL3 and its close relative
CCL5 (Blanpain et al., 2001). Work from the group of Osamu Yoshie
identiﬁed a transcript constitutively expressed in thymus and also
by PBMCs following activation with phytohaemagglutinin, which
they named Thymus and Activation-Regulated Chemokine (TARC)
(Imai et al., 1996) and which they subsequently showed to be a
high-afﬁnity ligand for CCR4, inducing chemotaxis and Ca2þ inﬂux
in CCR4 transfectants (Imai et al., 1997). Northern blot analysis in
the same manuscript showed CCR4 mRNA to be expressed by
human CD4þ T cells and a handful of T-cell lines including Hut-78
and Jurkat. Expression of CCR4 has subsequently been demon-
strated on several T-cell subsets including Th2 and T regulatory
(Treg) cells (discussed later) and more recently on Th17 (Acosta-
Rodriguez et al., 2007; Lim et al., 2008) and Th22 cells (Trifari
et al., 2009), where it is co-expressed with other chemokine re-
ceptors , notably CCR6.Shortly after the discovery of TARC, another CC chemokine was
cloned independently by two groups. The group of Patrick Gray at
ICOS Corporation named their discovery “monocyte derived che-
mokine” (MDC) since it was expressed by macrophages and
monocyte-derived dendritic cells (Godiska et al., 1997). Andrew
and colleagues at Amgen simultaneously cloned an identical CC
chemokine by EST sequencing of a cDNA library prepared from
activated macrophages which they named STCP-1 (Stimulated
T-cell chemotactic protein) since it recruited T-cells in chemotaxis
assays (Chang et al., 1997). Both groups subsequently showed that
the chemokines bound to the same chemokine receptor, namely
CCR4 (Andrew et al., 1998; Imai et al., 1998). TARC and MDC/STCP-
1 are now known as CCL17 and CCL22 respectively (Zlotnik and
Yoshie, 2000). Both CCL17 and CCL22 bind CCR4 with low nano-
molar afﬁnity and have similar potencies in chemotaxis assays,
although CCL22 is the slightly more efﬁcacious ligand of the two.
The genes for CCL17 and CCL22 reside in close proximity on hu-
man chromosome 16q13 suggesting that they arose by gene du-
plication, although the mature protein sequences are less than 40%
identical (Imai et al., 1998). Both CCL22 and CCL17 are expressed in
the thymus leading to the notion that one role of the receptor may
be to regulate the intrathymic movement of CCR4þCD4þCD8þ
thymocytes during the process of T lymphocyte education and
differentiation (Annunziato et al., 2000; Chantry et al., 1999).
1.6. CCR4 and its ligands in disease
1.6.1. Asthma
A considerable body of evidence points to a role for CCR4 and
its ligands in allergic diseases, notably asthma. Polarization of
human T-cells in vitro to Th2 subsets by culture with cytokine and
antibody cocktails (IL4, anti-IFNγ and anti-IL-10), has been well
documented to generate IL-4 producing Th2 cells, which express
CCR4 at both protein and message level (Bonecchi et al., 1998;
Sallusto et al., 1998). This facilitates their recruitment by dendritic
cells which produce CCL17 and CCL22 during maturation (Tang
and Cyster, 1999). Upregulation of CCR4 on T cells is mirrored
in vivo, with CCR4 expression a key feature of IL-4 producing T
cells recovered from the bronchoalveolar lavage ﬂuid of asthmatic
and healthy subjects CCR4 (Morgan et al., 2005; Panina-Bordignon
et al., 2001). The CCR4 ligands CCL22 and CCL17 are also upregu-
lated in the lung following allergen challenge (Bochner et al.,
2003; Pilette et al., 2004). More recently, a study by Vijayanand
and colleagues demonstrated increased CCR4 expression on T cells
isolated from patients with asthma. They also notably demon-
strated that CCL17 but not CCL22 was signiﬁcantly upregulated
following challenge of ex vivo airway biopsies with house dust
mite extract (Vijayanand et al., 2010).
A role for CCR4 expression on bronchial epithelial cells has
been discovered (Bonner et al., 2013). Interestingly, previous stu-
dies reported that bronchial epithelial cells in culture can also
produce CCL17 (Sekiya et al., 2000), highlighting the potential for a
positive feedback signaling loop. We have recently shown that
CCR4 is expressed by both primary bronchial epithelial cells and
lines such as BEAS2B, and can bind and internalize CCR4 in re-
sponse to ligand. Notably, we observed that CCL17 was an ex-
tremely efﬁcacious inducer of α-CGRP synthesis and release
(Bonner et al., 2013). This, we hypothesize, may play a pathological
role in asthma, since α-CGRP production is markedly increased in
the airways of asthmatic patients challenged with allergen-de-
rived T-cell peptides (Kay et al., 2007). α-CGRP is known to act
synergistically with other mediators of inﬂammation, including
histamine, to produce marked and prolonged edema, thus con-
tributing to pathology (Brain and Williams, 1985). Curiously, in
contrast to CCL17, CCL22 is a feeble inducer of α-CGRP release,
with an approximately 10,000-fold reduction in activity compared
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(Imai et al., 1998; 1997). To our knowledge, this is the ﬁrst pub-
lished description of a deﬁnitive physiological outcome by an en-
dogenous biased agonist of a chemokine receptor.
Data obtained in humans has been corroborated to a certain
extent by rodent models of allergic airways disease. Mikhak et al
showed that antigen-speciﬁc Th2 cells adoptively transferred from
CCR4-deﬁcient mice fail to trafﬁc in signiﬁcant numbers to the
allergic lung (Mikhak et al., 2009). Similarly, antibody neutraliza-
tion of either CC17 or CCL22 proved to be effective in reducing
leukocyte recruitment to the lung and associated parameters of
inﬂammation, following allergen challenge (Kawasaki et al., 2001;
Lloyd et al., 2000). In contrast to these studies, ovalbumin chal-
lenged CCR4 null mice were not protected against airways in-
ﬂammation compared with littermates (Chvatchko et al., 2000),
nor were ovalbumin challenged guinea pigs protected from lung
inﬂammation when CCR4 was neutralized by an antibody (Conroy
et al., 2003). This suggests that the underlying biology of CCR4
may be subtly different in rodents and man. A recent study cir-
cumvented this by using a human PBMC-reconstituted SCID
mouse model and found that CCR4 blockade via a speciﬁc antibody
ablated many of the features of inﬂammation, including airway
eosinophilia, goblet cell hyperplasia, IgE synthesis and bronchial
hyper-reactivity, thus reinforcing the idea that CCR4 is a viable
target in the treatment of asthma (Perros et al., 2009).
1.6.2. CCR4 and its ligands in allergic dermatitis
The discovery by Campbell and colleagues that skin-homing
cutaneous lymphocyte antigen (CLA)þ T cells express high levels
of CCR4 expression (Campbell et al., 1999), implicated the receptor
in the pathology of atopic dermatitis. This was subsequently
supported by a study in which the levels of both CCR4 and CLA
were shown to be increased on the surface of peripheral blood
CD4þ T cells from severe atopic dermatitis subjects compared
with control subjects. CCR4 expression levels were also shown to
decrease as disease symptoms improved (Wakugawa et al., 2001).
In mouse models of cutaneous delayed type hypersensitivity, CCR4
has been shown to support the homing of T cells to skin (Reiss
et al., 2001). Several studies have reported elevated serum levels of
CCL17 in human atopic dermatitis subjects (Shimada et al., 2004)
with CCL17 thought to be produced by keratinocytes (Vestergaard
et al., 2000). Serum levels of the chemokine show close correlation
with disease severity (Kakinuma et al., 2001) . Indeed, out of a
panel of adult biomarkers, CCL17 was found by Kou et al to have
the highest odds ratio for the likelihood of having atopic derma-
titis (Kou et al., 2012). This is consistent with in vitro studies
showing that corneal and dermal ﬁbroblasts stimulated with the
Th2-associated cytokines IL-4 and IL-13 are important sources of
CCL17 (Fukuda et al., 2003). Human platelets have also been
shown to express CCR4 and to undergo aggregation following
stimulation with CCL17 and CCL22 (Abi-Younes et al., 2001;
Clemetson et al., 2000; Kowalska et al., 2000). This was postulated
by Abi-Younes and colleagues to explain the increased serum le-
vels of CXCL4 in a murine model of atopic dermatitis (Watanabe
et al., 1999), since CXCL4 is a marker of platelet degranulation.
Moreover, since platelets have been shown to contain CCL17 there
is potential for positive feedback in this process (Fujisawa et al.,
2002).
1.6.3. CCR4 and its ligands in T-cell neoplasms
Working with the hypothesis that the chemokine expression
pattern of T-cell neoplasm may give insight into their cellular
origins, the group of Osamo Yoshie were ﬁrst to show that CCR4
was expressed at consistently high levels on the surface of a wide
range of human T-cell lines (Yoshie et al., 2002), including Hut87
and Jurkat lines, which they had previously examined by Northernblot analysis (Imai et al., 1997). Using a panel of 24 adult adult T
cell lymphoma patients, the vast majority of PBMCs from these
subjects (22/24) were shown to express CCR4 by PCR and to re-
spond to CCL17 and CCL22 in chemotaxis assays (Yoshie et al.,
2002). Subsequent studies by others conﬁrmed the expression of
CCR4 in archived adult T cell lymphoma tissues (Ishida et al., 2003)
and also showed CCR4 to be abundantly expressed by other neo-
plasms including some peripheral T cell lymphoma and NK cell
lymphomas (Ishida et al., 2004) and cutaneous T cell lymphomas
(Campbell et al., 2010; Ferenczi et al., 2002). Subsequent studies
addressing the molecular mechanisms for CCR4 upregulation,
found the transcription factor FRA-2 to be signiﬁcantly upregu-
lated in adult T cell lymphoma and to drive enhanced CCR4 ex-
pression and proliferation of both adult T cell lymphomas and
cutaneous T cell lymphoma s (Nakayama et al., 2007; 2012). A
recent study has described mutations in the C-terminus of CCR4
that truncate the receptor and lead to a gain of function, with
respect to enhanced cellular signaling, chemotaxis and prolifera-
tion (Nakagawa et al., 2014). These are remarkably similar to
truncating mutations in CXCR4 that have been described as ex-
acerbating signaling in WHIM syndrome patients (Hernandez
et al., 2003).2. Blockade of CCR4 in the treatment of disease
2.1. Anti-CCR4 biologicals
Monoclonal antibodies targeting CCR4 have been described by
several groups. Our own group, in collaboration with scientists at
LeukoSite/Millennium Pharmaceuticals characterized a panel of
CCR4-speciﬁc antibodies which were generated by immunization of
mice with transfectants expressing the receptor (Andrew et al.,
2001). The most promising of these was a molecule known as 10E4
which recognizes an N-terminal epitope of CCR4 (Jopling et al., 2002)
and which we subsequently used to neutralize CCR4 in a guinea pig
model of allergic airways disease (Conroy et al., 2003). Scientists at
Kyowa Hakko Kogyo generated a murine monoclonal antibody
named KM-2160 by immunizing mice with a peptide corresponding
to amino acid residues 2–29 of the human CCR4 N-terminus (Ishida
et al., 2003). Using this mAb, they showed that increased levels of
CCR4 staining on primary adult T cell lymphoma cells correlated with
decreased survival of the patient. This ﬁnding spurred on the authors
to assess the efﬁcacy of this antibody in mediating antibody-de-
pendent cellular cytotoxicity, turning CCR4 into a target by which
adult T cell lymphomas could be sought out and destroyed by host
NK cells. The antibody underwent subsequent modiﬁcations, namely
cDNAs encoding the heavy- and light chain variable region of the
KM-2160 hybridoma were cloned into an IgG1 antibody expression
vector and the construct expressed in the rat myeloma cell line YB2/
0. From the supernatant they were able to purify a chimeric anti-
CCR4 antibody which they named KM-2760 (Niwa et al., 2004). This
antibody has low levels of fucosylation in the Fc region (7%), which
they showed corresponded to greater activity in antibody-dependent
cellular cytotoxicity assays. KM2760 then underwent full humani-
zation to generate the mAb KW-0761 (also known as mogamulizu-
mab) which demonstrated potent antitumor activity against primary
adult T cell lymphomas both in vitro and ex vivo (Ishii et al., 2010).
Mogalizumab subsequently entered clinical trials for the
treatment of both adult T cell lymphoma and peripheral T cell
lymphoma and was found to be well tolerated, have a half life of
around 18 days and meet preliminary objective responses (Ya-
mamoto et al., 2010). Subsequent phase II studies of relapsed adult
T cell lymphoma patients (Ishida et al., 2012) and relapsed per-
ipheral T cell lymphomas and cutaneous T cell lymphomas (Ogura
et al., 2014) found mogalizumab to again show efﬁcacy, with
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groups. In 2012, mogalizumab was granted approval for the
treatment of relapsed or refractory adult T cell lymphoma in Japan.
2.2. Small molecule antagonists of CCR4
Given the importance of CCR4 and its ligands in allergic in-
ﬂammatory diseases there has been a signiﬁcant effort over many
years to discover small molecule CCR4 antagonists. However, de-
spite all these endeavors, so far only one molecule has made it to
human clinical trials and that too appears to have been terminated
(Cahn et al., 2013; Solari et al., 2014). Chemokine receptors are
GPCRs, which are historically the most successful target class forFig. 2. The chemical structures of a handful of small modrug discovery, so this lack of success has been surprising and has
been attributed to many factors (Solari et al., 2014).
The patent literature for CCR4 antagonists began to emerge
around 2002 and the ﬁrst comprehensive review of the ﬁeld in
2006 revealed that these could be divided into four main groups;
aryl sulphonamides, substituted amino heterocycles, thiazolidi-
nones and lactams (Purandare and Somerville, 2006). Since then
there have been many reports of CCR4 antagonists that can
grouped into two main chemical categories. The ﬁrst is a collection
of lipophilic heteroarenes from Bristol Myers Squibb, Astellas and
Daiichi Sankyo and the second is a range of aryl sulphonamides
from Astra Zeneca, Ono and GlaxoSmithKline (Andrews et al.,
2007; Banﬁeld et al., 2010; Burdi et al., 2007; Cahn et al., 2013;lecule CCR4 antagonists described in the main text.
Fig. 3. A diagram representing various modes of allosteric modulation at CCR4. The
left panels shows transmembrane helices II and III of CCR4 being activated by
chemokine (space ﬁlled model). The centre panel shows a "Site 1" antagonist
(yellow) bound to an intrahelical binding site. The right panel shows a lipophillic
"Site 2" antagonist (cyan) interacting with C-terminal helix VIII of CCR4.
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et al., 2013; 2012; Purandare et al., 2007; Solari et al., 2014; Yo-
koyama et al., 2009; 2008; Zhao et al., 2009). Some pertinent
structures from these studies are shown in Fig. 2. A number of
these compounds looked very promising and showed efﬁcacy in
animal models of allergic inﬂammation however only one, an in-
dazole arylsulfonamide, GSK 2239633 (Slack et al., 2013) appears
to have progressed to clinical trials (Cahn et al., 2013).
Clues began to emerge about the complex biology of CCR4 that
might explain why drug discovery has been so challenging. The
ﬁrst came from studies by Astra Zeneca on a series of pyrazinyl-
sulfonamides that were allosteric antagonists of CCR4 and that
appeared to bind to an intracellular site on the receptor, the so-
called “Site 2” (Andrews et al., 2007). Furthermore, it appeared
that this intracellular allosteric binding site was different to the
site bound by the compound BMS-397 (“Site 1”) and both of these
antagonist sites were distinct from the binding site for the natural
ligands (Ajram et al., 2014). Unpublished mutagenesis work from
our groups suggests that “Site 1” resides in a well characterized
hydrophobic pocket comprised of resides in transmembrane helix
III, whilst “Site 2” is centered around the cytoplasmic Helix VIII
thought to run parallel to the lipid bilayer (Fig. 3).
In addition to this complex pharmacology it appears the re-
ceptor displays complex biological responses to its natural ligands.
Like most GPCRs, CCR4 is internalised following agonist binding as
part of the desensitisation process. However, it appeared that the
two natural CCR4 ligands, CCL17 and CCL22, induced different
rates of receptor internalisation (Imai et al., 1998; Mariani et al.,
2004). Moreover, this difference in receptor trafﬁcking was re-
ﬂected by small molecule antagonists. Arylsulphonamides that
bind to the intracellular allosteric site were unable to induce re-
ceptor internalisation whereas lipophilic amine antagonists bind-
ing to the extracellular site were (Ajram et al., 2014). The possi-
bility that receptor down regulation by antagonists may contribute
to the inhibition of a biological response was highlighted by stu-
dies of another CCR4 antagonist, K777 (Sato et al., 2013). Thus this
chemokine receptor, and perhaps others, shows complex regula-
tion of cell surface expression and trafﬁcking that may in part
reﬂect the need for accurate control of chemotaxis signals. In ad-
dition to differences in receptor trafﬁcking, the two natural ligands
also showed differences in receptor coupling with CCL22 coupling
to arrestin signaling, whereas CCL17 does not (Ajram et al., 2014).3. Conclusions
Clearly CCR4 is amenable to the discovery of drug-like an-
tagonists, however the failure of these to translate small moleculesinto drugs raises the question that perhaps we still do not ap-
preciate the subtle and complex biological controls that regulate
the function of this receptor. For example, what are the relative
contributions of arrestins to CCR4-mediated signalling? Which
members of the GRK family govern CCR4 desentization and traf-
ﬁcking? An obvious potential caveat of total CCR4 blockade as an
asthma treatment is the potential for the impairment of regulatory
T cell recruitment, since T-regulatory cells (Tregs) have been
shown to express CCR4 and to migrate in vitro in response to both
CCL17 and CCL22 (Iellem et al., 2001). Blockade of CCR4 function
on these cells might therefore be envisaged to worsen rather than
dampen allergic inﬂammation since Tregs have the capacity to
suppress Th2-mediated inﬂammation in vivo (Saito et al., 2008).
Indeed, mogalizumab treatment has been associated with several
cases of severe skin inﬂammation, notably Steven–Johnson syn-
drome, which in one case proved to be fatal (Ishida et al., 2013).
Examination of one Steven–Johnson syndrome patient revealed a
signiﬁcant reduction in staining for the Treg marker FOXP3, in
both PBMCs and skin lesions, incriminating Treg depletion in the
pathogenesis. The efﬁcacy of mogamulizumab in the treatment of
CCR4-negative solid cancers, where Treg depletion is desirable, is
currently being assessed. A recent report outlining the treatment
of four elderly patients with mogalizumab has also suggested that
an additional side-effect may be the risk of opportunistic infection
with cytomegalovirus (Ohyama et al., 2014).
However, it may be possible to employ small molecules to block
the activity of one CCR4 agonist whilst sparing another, since they
are biased agonists with respect to arrestin coupling (Ajram et al.,
2014) and also with respect to αCGRP induction in bronchial
epithelial cells (Bonner et al., 2013). In a proof of principle ap-
proach, we have recently shown that CCL22 signaling can be
spared whilst ablating CCL17 signaling by the use of a CCR4-spe-
ciﬁc mAb 10E4 which binds the receptor N-terminus (Viney et al.,
2014). This mAb presumably preferentially inhibits a CCR4 con-
formation required for CCL17 signaling but dispensable for CCL22
signaling. This may be important in dialing out the off-target ef-
fects of inhibiting Treg recruitment, since their recruitment by
activated dendritic cells appears to be mediated principally via
CCL22 (Iellem et al., 2001). Analysis of the structure–activity re-
lationship of existing compounds with attention to the signaling
pathways blocked by the compounds could be a fruitful approach
to ﬁne-tune these compounds into molecules which block CCL17
but spare CCL22 signaling.Acknowledgements
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